Most of the sample was defined as having definite NASH or borderline NASH at baseline (83.2%) with mean NAFLD Activity Score (NAS) 4.58 ± 1.49 and mean ALT 120.9 ± 65.1 U/L (Table 1). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.